Table 3

Characteristics of identified neoantigen-specific T cell responses in TIL infusion products

Gene mutationWT peptideMutant peptideFrequency (% multimer+CD8+ T cells of total CD8+ T cells)Restriction element
Patient 3RBM12 S>L SPHEAGFCV LPHEAGFCV29.00HLA-B*51:01
VARS T>M EVADEATGALEVADEAMGAL0.096HLA-A*25:01
MYLK G>V EVFPEDTGTYEVFPEDTVTY1.90HLA-A*25:01
LRP3 T>S LTAARPSQTVLLTAARPSQSVL0.039HLA-A*25:01
WDR1 N>K DSFAGKGHTN DSFAGKGHTK 0.50HLA-A*68:01
Patient 4TTC37 A>V YLDGKAVDYYLDGKVVDY1.14HLA-A*01:01
ENTPD4 P>L ATDTNNPNVNYATDTNNLNVNY3.35HLA-A*01:01
MAB21L1 V>M LRIRDRYVV LRIRDRYVM 0.007HLA-B*08:01
Patient 8RAD51AP1-002 S>F KVKSPVEKKKVKFPVEKK0.195HLA-A*03:01
  • TIL, tumor infiltrating lymphocyte.